Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announced that its clinical facility in Mexico City has begun recruiting patients for Group Two of its ongoing human clinical study of the Ocumetics Lens, a next-generation accommodating intraocular lens. The surgeries are targeted for Fall 2026, marking a significant step in the company's clinical development program.
Unlike the first group, which focused solely on safety, the Group Two study will evaluate both safety and vision performance, specifically near and distance vision. This expansion reflects the company's confidence in the technology's safety profile and its commitment to demonstrating functional benefits. The patients in this group will receive the latest-generation Ocumetics Lens, which incorporates design advancements and will be implanted using an enhanced delivery system.
The initiation of patient recruitment coincides with an important milestone: Group One patients are reaching their 12-month follow-up visits, providing longer-term clinical data. The positive outcomes from Group One, which met and exceeded expectations regarding safety, performance, and handling, have paved the way for this next phase. Dean Burns, President and CEO of Ocumetics, expressed excitement about the progress, stating, "We are extremely excited to begin the process of moving into our larger Group Two study. Commencement of this study represents another important milestone in the continued clinical development of the Ocumetics Lens."
The Group Two study is designed to provide critical evidence on the lens's ability to restore a full range of vision, potentially eliminating the need for glasses or contact lenses. The Ocumetics Lens is designed to fit within the eye's natural lens compartment and utilize the eye's natural muscle activity to shift focus dynamically, offering clear vision at all distances without perceptible time lag. This technology could transform the ophthalmic industry, offering a solution for presbyopia and cataracts that goes beyond current monofocal or multifocal lenses.
The company's progress is particularly noteworthy given the challenges of developing such innovative intraocular lenses. The commencement of Group Two recruitment not only demonstrates the company's ability to execute its clinical plan but also suggests that the technology is advancing toward potential commercialization. As the company continues to gather data, it will be crucial to monitor the long-term safety and efficacy results from both Group One and Group Two patients.
Ocumetics is a Canadian research and product development company focused on advanced vision correction solutions. With this clinical advancement, the company is positioning itself at the forefront of intraocular lens technology. The success of Group Two could pave the way for larger pivotal trials and eventual regulatory approvals, bringing the company closer to delivering a truly differentiated solution for patients seeking improved vision.
